PDCD1 and melanoma: Moreover, there is an increasing tendency to employ immune checkpoint inhibitors earlier in the disease process, with pembrolizumab (anti-PD-1) now licensed for completely resected melanoma from stage IIB/C, i.e., in the absence of metastatic disease [8].